Quark grants Novartis siRNA option

Quark Pharmaceuticals Inc. (Fremont, Calif.) granted Novartis AG (NYSE:NVS; SIX:NOVN) an option to license exclusive, worldwide rights to QPI-1002. The short interfering RNA (siRNA) inhibitor of p53 e...